First AD

Second AD

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLC

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024

OncLive News Network®

Memorial Sloan Kettering Cancer Center 

Cancer Centers

Partner

Testing for ALK Fusions and ROS1 Rearrangements in NSCLC

Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial

Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors

Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy

Future Research Directions in ALK+ and ROS1+ NSCLC